Traws Pharma
TRAW
26 hedge funds and large institutions have $1.37M invested in Traws Pharma in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
8% more capital invested
Capital invested by funds: $1.27M → $1.37M (+$96.9K)
0.01% more ownership
Funds ownership: 0.34% → 0.35% (+0.01%)
4% less funds holding
Funds holding: 27 → 26 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$101K |
| 2 |
Morgan Stanley
New York
|
+$12K |
| 3 |
Renaissance Technologies
New York
|
+$10.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.16K |
| 5 |
Millennium Management
New York
|
+$2.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$58K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.2K |
| 3 |
Two Sigma Advisers
New York
|
-$11.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$7.78K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$681 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Qube Research & Technologies (QRT)
London,
United Kingdom
| $2 | – | – | – |
|
|
27
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$22.2K | -1,229 | Closed |
|
|
TSS
28
Two Sigma Securities
New York
| – | -$7.78K | -437 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$136 | +8 | +100% |
|
TRAW Hedge Fund Activity: Q4 2023 in Review
26 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2023, worth a combined $1.37M — up 7.6% from $1.27M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TRAW and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 7 added.
The largest buyer was Marex Group, opening a new position worth an estimated $101K. The largest seller was Two Sigma Investments, cutting an estimated $58K.
- 26 institutional investors held Traws Pharma (TRAW) as of Q4 2023, down from 27 in Q3 2023.
- Funds reported $1.37M of Traws Pharma stock for Q4 2023, up 7.6% quarter-over-quarter.
- 2 funds opened new Traws Pharma positions in Q4 2023 and 3 closed out, a net change of -1 holder.
- The largest Traws Pharma buyer in Q4 2023 was Marex Group, an estimated $101K added.
- The largest Traws Pharma seller in Q4 2023 was Two Sigma Investments, an estimated $58K sold.
Based on aggregated 13F filings for Q4 2023.